ContractAllovir, Inc. • June 3rd, 2020 • Biological products, (no disgnostic substances) • Tokyo
Company FiledJune 3rd, 2020 Industry Jurisdiction
VIRACYTE, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • June 3rd, 2020 • Allovir, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledJune 3rd, 2020 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the [8th] day of May, 2019, by and among ViraCyte, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Founder” that becomes a party to this Agreement in accordance with Section 6.9 hereof.
ASSET RENTAL AGREEMENTAsset Rental Agreement • June 3rd, 2020 • Allovir, Inc. • Biological products, (no disgnostic substances) • Massachusetts
Contract Type FiledJune 3rd, 2020 Company Industry JurisdictionTHIS ASSET RENTAL AGREEMENT (“ERA”), effective as of May 1, 2019, (the “Effective Date”) is made by and between ElevateBio Management, Inc., a Delaware Corporation with an office at 139 Main Street, Suite 500, Cambridge, MA 02142, (“ElevateBio”) and Allovir, Inc., a Delaware Corporation with an office at 2925 Richmond Ave., Suite 1274, Houston, Texas 77098 (“Allovir”).